Back to search

Boston University

Evaluation of viral therapy for cancer treatment

Abstract

dc:description.abstract

Cancer has been increasing and has a profound impact on society. Current treatments are known to have limits so searching for more effective cancer treatments have led scientists to theorize using viruses. Viruses are submicroscopic and consist of nucleic acid that’s either RNA or DNA and can be single-stranded or double-stranded. Oncolytic Viruses uses a virus’s natural ability to infect certain cells to target and destroy cancer cells through cell lysis, apoptosis, and modifications of the cell surface membrane. They can carry transgenes such as GM-CSF, which promotes host immune responses. Oncolytic activities such as local replication and propagation also induce cytokines that engage the immune system to increase antitumor immunity. T-Vec is an oncolytic viral drug that’s recently approved for use, and many other drugs are in clinical trials awaiting approval. The common goal of these drugs is prolonging the survival of cancer patients and inducing patient specific anti-tumor immunity. These drugs have certain advantages over traditional therapies but also potential risks; a proposed study to analyze G47Δ can be used to explore the safety and efficacy of oncolytic viruses compared to traditional therapies such as chemotherapy. In this proposed study, subjects over the age of 18 are studied longitudinally over 5 years. Two hundred participants with advanced stage melanoma, breast cancer, and/or prostate cancer, where radiation and chemotherapy have not slowed the progression of disease, are enrolled and split into two groups receiving either Paclitaxel and Docetaxel or 3 x 10^8 pfu of G47Δ injected intravenously. They are monitored for severity with the statistics averaged together and a standard deviation computed for all the data. Overall, viral therapy has been shown to have a tolerable safety profile with only low-grade adverse events and largely non-overlapping toxicity with other cancer therapeutics. This is especially true given the number of late-stage patients enrolled in these studies, the severity of their diseases, as well as the side-effects associated with chemotherapy and radiation. While usage of oncolytic viral therapies is currently still low, it is hoped that it will not be long before this becomes a standard option for treatment of all cancer patients.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2022

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Lu, Kevin
Advisors dc:contributor.advisor
  • Young, Aaron W.
  • Flynn, David

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/45607

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Lu, Kevin. Evaluation of viral therapy for cancer treatment. masters thesis, Boston University, 2022. https://hdl.handle.net/2144/45607